Related references
Note: Only part of the references are listed.Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients
Yang Li et al.
SCIENTIFIC REPORTS (2021)
Lipoprotein-associated phospholipase A2: The story continues
Fubao Huang et al.
MEDICINAL RESEARCH REVIEWS (2020)
High levels of modified ceramides are a defining feature of murine and human cancer cachexia
Pauline Morigny et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Effect of acyl and alkyl analogs of platelet-activating factor on inflammatory signaling
Gopal Kedihithlu Marathe et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2020)
Energy metabolism in cachexia
Maria Rohm et al.
EMBO REPORTS (2019)
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019
Stephan von Haehling et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Cancer-associated cachexia
Vickie E. Baracos et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Inter-tissue communication in cancer cachexia
Josep M. Argiles et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer
Francesca Tavano et al.
SCIENTIFIC REPORTS (2018)
Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment
Norbaini Binti Abdol Razak et al.
CANCERS (2018)
Should omega-3 fatty acids be used for adjuvant treatment of cancer cachexia?
Daryna Sergiyivna Lavriv et al.
CLINICAL NUTRITION ESPEN (2018)
Cancer Cachexia: More Than Skeletal Muscle Wasting
Soren Fisker Schmidt et al.
TRENDS IN CANCER (2018)
Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent
C. J. Reddel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Biomarkers of cancer cachexia
Audrey Loumaye et al.
CLINICAL BIOCHEMISTRY (2017)
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells
Laura Lehtinen et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2017)
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
Jennifer S. Temel et al.
LANCET ONCOLOGY (2016)
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
Jeffrey Crawford et al.
CURRENT ONCOLOGY REPORTS (2016)
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema A 3-Month Placebo-Controlled Study
Giovanni Staurenghi et al.
OPHTHALMOLOGY (2015)
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins
Paula Vainio et al.
Oncotarget (2015)
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial
Michelle L. O'Donoghue et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase
Gopal Kedihitlu Marathe et al.
JOURNAL OF LIPID RESEARCH (2014)
Unraveling the PAF-AH/Lp-PLA2 controversy
Diana M. Stafforini et al.
JOURNAL OF LIPID RESEARCH (2014)
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Harvey D. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Why cachexia kills: examining the causality of poor outcomes in wasting conditions
Kamyar Kalantar-Zadeh et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2013)
Selective enrichment of newly synthesized proteins for quantitative secretome analysis
Katrin Eichelbaum et al.
NATURE BIOTECHNOLOGY (2012)
The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice
Miao-miao Hu et al.
ACTA PHARMACOLOGICA SINICA (2011)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
Inhibition of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Decreases Atherosclerotic Plaque Formation in ApoE-Deficient Mice
Wen-yi Wang et al.
PLOS ONE (2011)
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
LANCET (2010)
Epidemiology of cancer-related venous thromboembolism
Ted Wun et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer
D. A. C. Deans et al.
BRITISH JOURNAL OF CANCER (2009)
Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke -: A population-based cohort study from Malmo, Sweden
Margaretha Persson et al.
ATHEROSCLEROSIS (2008)
Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages
Katarina E. Olofsson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease
Marc S. Sabatine et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
CM Ballantyne et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up
ES Brilakis et al.
EUROPEAN HEART JOURNAL (2005)
Prognosis of cancers associated with venous thromboembolism.
HT Sorensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study
JA Heit et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
